Bromometric analysis of Lamotrigine, Minoxidil and Cefixime

 

A. Aboul-Kheir, Hanaa Saleh, Magda M. El-Henawee and M.N. Sharf El-Din

Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.

*Corresponding Author E-mail: dr_moh0300@yahoo.com

 

ABSTRACT:

Two spectrophotometric methods are described for determination of Lamotrigine, Minoxidil and Cefixime in bulk and pharmaceutical dosage forms using insitu generated bromine as oxidizing agent and either methyl orange or methylene blue as chromogenic agents. Drugs are treated with known excess of bromine and residual unreacted bromine is determined by treating with fixed amount of either methyl orange and measuring absorbance at 508 nm or methylene blue and measuring absorbance at 667 nm for minoxidil and lamotrigine and at 747 nm for cefixime. The amount of bromine reacted corresponds to the amount of each drug. Calibration curves were linear over ranges of 4.0 – 30.0, 0.5 – 4.0 and 0.5 – 5.0 µg.ml-1  for lamotrigine, minoxidil and cefixime, respectively in case of methyl orange and of  5.0 – 40.0, 0.5 – 7.0 and 2.0 – 5.5 µg.ml-1 for lamotrigine, minoxidil and cefixime, respectively in case of methylene blue. The methods were satisfactory applied for the determination of drugs in both bulk and pharmaceutical forms and results were compared statistically with reference methods.

 

 


INTRODUCTION:

Lamotrigine is (6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine).(1) It blocks voltage-gated sodium channels in presynaptic neurons and inhibits the release of glutamate. It displays neuroprotective effects in various models and is a clinically useful anti-epileptic agent.(2) Various analytical techniques have been employed for the determination of lamotrigine in pure and dosage forms including HPLC,(3-7) gas chromatography,(8,9) thin-layer chromatography,(10) capillary electrophoresis,(11,12) spectrophotometry,(13-15) adsorptive stripping voltammetry,(16) selective membrane electrode,(17) Immunofluorimetric assay(18) and radioimmunoassay.(19)

Minoxidil is (6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide).(1) It is a peripheral vasodilator and it is used in scalp preparations for hair loss.(2) Several methods were reported for the determination of minoxidil in pure and dosage forms including HPLC,(20-22) Gas-chromatography,(23) capillary isotachophoresis,(24) derivative spectrophotometry,(25) Integrated flow injection-solid phase spectrophotometry,(26) spectrophotometry(27-31) and differential pulse polarography.(32)

 

Cefixime is [(6R,7R)-7-[[(Z)-2-(2-aminothiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid trihydrate].(1) It is generally classified as third generation cephalosporin antibiotic and is given by mouth in the treatement of susceptible infections including gonorrhoea, otitis media, pharyngitis, lower respiratory tract infections such as bronchitis and urinary tract infections.(2) It is reported to be determined through many techniques including HPLC,(33-37)  HPTLC(38), capillary zone electrophoresis(39,40), voltammetry(41,42), selective membrane electrode(43), Spectrophotometry(33,44-47) and spectrofluorimetry( 47,48).

 

Minoxidil

Lamotrigine

Cefixime

 

2. EXPERIMENTAL:

2.1. Apparatus

All of the spectrophotometric measurements were carried out using a Shimadzu UV-1800 with matched 1 cm quartz cells. A Lutron digital pH-meter was used for pH adjustment.

 

2.2. Materials and reagents

All solvents and reagents were of analytical grade and double distilled water was used throughout the work. Lamotrigine (Delta Pharm, 10th of Ramadan city, Egypt) working solution 5 µg.ml-1 was prepared by dissolving in least amount of DMF then completing to volume with distilled water.

 

Minoxidil ((Delta Pharm, 10th of Ramadan city, Egypt) working solution 5 µg.ml-1 was prepared by dissolving in least amount of methanol then completing to volume with distilled water.

 

Cefixime (Sigma Pharmaceuticals, Kwesna, Egypt) working solution 5 µg.ml-1 was prepared by dissolving in distilled water. 5 M HCl (El-Nasr Chemicals, Egypt) was prepared by diluting 225 ml of concentrated HCl (36%) to 500 ml. 

 

Methyl Orange (Fluka, Switzerland) 20 mg/100 ml dissolved in and completed to 100 ml mark with distilled water and filtered (stable for 2 weeks at least).

 

Methylene blue (Fluka, Switzerland) 20 mg/100 ml dissolved in 20 ml methanol then completed to 100 ml with distilled water (stable for 2 weeks at least).

 

Bromide/bromate stock solution were prepared by dissolving 100 mg of potassium bromate (Winlab, England) and 1.0 gm of potassium bromide (Winlab, England) in 100 ml distilled water (stable for 10 days at least). Working solution was freshly prepared daily by diluting 2.5 ml of stock solution to 100 ml with distilled water.

 

2.3. Pharmaceutical preparations

The following available pharmaceutical preparations were analyzed

Lamotrine® tablets labeled to contain 25 mg per tablet. Batch No. MT1960807 (Multi Apex  Pharm. Company, Badr City).

Ximacef® Capsules labeled to contain 400 mg cefixime per capsule. Batch No.90640 (Sigma Pharmaceuticals, Kwesna, Egypt).

 

Performa® lotion 5% Batch # 80163 (Delta Pharm Company, 10th of Ramadan, Egypt).

 

2.3. Procedure

2.3.1. General spectrophotometric procedure for determination of Lamotrigine, Minoxidil  and Cefixime.

2.3.1.1. Lamotrigine           

To 0.5 ml bromate working solution add 0.1-2 ml (0.5 to 20 µg/ml) drug then acidify using 1 ml 5 M HCl and stand for 5 minutes, add 1.0 ml dye working solution then stand for 5 minutes and complete to 10 ml mark with distilled water then measure absorbance against reagent blank similarly prepared at 667 nm or 508 nm for methylene blue or methyl orange, respectively.

 

2.3.1.2. Minoxidil

Mix 1.0 ml of bromate working solution with 0.1- 2 ml (0.5 to 20 µg/ml) drug in 10 ml measuring flask and add 1 ml 5 M HCl stand for 5 minutes, add 1 ml dye working solution and stand for 5 minutes and complete to 10 ml mark with distilled water then measure absorbance against blank similarly prepared at 667nm or 508 nm for methylene blue or methyl orange, respectively.

 

2.3.1.3. Cefixime

In 10 ml measuring flask place 1 ml bromate working solution, 0.1- 2 ml (0.5 to 20 µg/ml) drug, acidify with 4 ml 5 M HCl, stand for 15 minutes then add 0.5 ml dye and wait for 5 minutes before diluting to 10 ml with distilled water and measure absorbance at 747 nm or 508 nm for methylene blue or methyl orange, respectively against reagent blank similarly prepared.

 

In the stated methods calibration graph was prepared by plotting absorbance versus concentration of drug and the concentration of the unknown was computed from the regression equation derived from the Beer’s law data.

 

2.3.2. Procedure for pharmaceutical preparations

For Lamotrine® tablets: 10 tablets were crushed and a weight equivalent to two tablets was taken, extracted three successive times with 20 ml DMF, filtered into 100 ml measuring flask and then completed to volume with distilled water. Then follow the same procedures described for determination as in authentic sample. 

 

For Performa® lotion: Transfer 1.0 ml of lotion to 50 ml measuring flask then complete to mark with distilled water. Then follow the same procedures described for determination as in authentic sample.

 

For Ximacef® capsules contents of 10 capsules were obtained and weight equivalent to 500 µg was taken, extracted three successive times with methanol, filtered into 100 ml measuring flask and then completed to volume with distilled water. Then follow the same procedures described for determination as in authentic sample.  

 

2.3.3 Reference method procedure for Lamotrigine determination (49) (according to Delta Pharm.) Amount equivalent to 10 mg was extracted with methanol three times, filtered, washed into 100 ml measuring flask and completed to volume with dist. Water. Known volumes were taken into 10 ml measuring flask and completed to volume with 0.1 M HCl then absorbance was measured at 267 nm against blank.

 

3. RESULTS AND DISCUSSION:

The proposed spectrophotometric methods are indirect and are based on the determination of the residual bromine (insitu generated) after allowing the reaction between each drug and a measured amount of bromine to be complete. The surplus bromine was determined by reacting it with a fixed amount of either methylene blue or methyl orange dye. The methods rely on the bleaching action of bromine on the dyes, the discoloration being caused by the oxidative destruction of the dyes. Lamotrigine, minoxidil or cefixime when added in increasing amounts to a fixed amount of insitu generated bromine, consumes the latter proportionately and there occurs a concomitant fall in the concentaration of bromine. When a fixed amount of dye is added to the decreasing amounts of bromine, a concomitant increase in the concentration of dye results. Consequently, a proportional increase in the absorbance at the respective λmax is observed with increasing concentration of each drug.

 

The insitu generation of bromine is carried  out using a mixture of potassium bromide and potassium bromate in presence of 5 M HCl  according to the following equation:

            5Br- + BrO3- + 6H+                                        3Br2 + 3H2O

 

3.1. Absorption spectra

The resulting absorption spectra are due to the red colour of residual unoxidized methyl orange at 508 nm (fig 1) or blue colour of residual unoxidized methylene blue at 667 nm for lamotrigine and minoxidil and at 747 for cefixime as both minoxidil and lamotrigine are analyzed in presence of 1.5 ml 5N HCL while cefixime is analyzed in presence of 4 ml 5N HCl (Fig 3).

 

Fig 1: Absorption spectra of methyl orange in presence of 5µg/ml Lamotrigine(A),  5µg/ml Minoxidil (B) and 5µg/ml Cefixime (C).  

 

Methylene blue exhibited two types of absorption spectra according to different volumes of  hydrochloric acid. In low HCl concentration (1 ml 5N HCl and complete to 10 ml) it exhibits peak maximum at 666 nm and in high HCl concentration (4 ml 5N HCl and complete to 10 ml) it exhibits peak maximum at 745 nm. A detailed investigation regarding different forms of methylene blue was carried out(52) proving the reasons for variation in absorption maximum at different acidities. Fig 2

                                                         

Fig 2: Absorption spectra of methylene blue against blank in weak acidic medium     (A) and in strong acidic medium (B)

 

Fig 3: Absorption spectra of methylene blue in presence of 20µg/ml Lamotrigine(A),  10µg/ml  Minoxidil(B) and 10µg/ml Cefixime (C)

 

3.2. Effect of dye concentration

Experiments were performed to found appropriate dye concentrations by stabilizing other experimental conditions and using different volumes of dyes and results illustrated that increasing dye volume above 1ml in case of lamotrigine and minoxidil does not result in change of absorption while only 0.6 ml were sufficient in case of Cefixime.(Fig 4 and 5)

 

Fig.(4) Effect of methyl orange concentration  on absorption intensity.

 

Fig.(5) Effect of methylene blue  concentration  on absorption  intensity.

 

3.3. Effect of Acidity

Different acids were tested as a medium for bromine generation including sulphuric acid, hydrochloric acid, nitric acid and phosphoric acid. Hydrochloric acid produced the most precise and accurate results. Therefore, 5 M HCl was used throughout experiments and it was found that 0.5-2 ml 5 M HCl is the appropriate acid volume for determination of Lamotrigine and increasing HCl volume above 2 ml result in a rapid decrease in absorption. While, 1.0-4.0 ml 5 M HCl is suitable for Minoxidil analysis. And 2.0-5.0 ml 5 M HCl is the appropriate volume in case of Cefixime. And this indicates that the specified acid concentration for bromination reaction was not critical.

 

3.3. Effect of time

Time required to brominates and oxidize the drug before addition of dye and time required to irreversibly oxidize dye after its addition was studied throughout different experiments using both of dyes. It was found that the bromination reaction was found to be complete in 5 minutes for lamotrigine and minoxidil and in 15 minutes in case of cefixime and after oxidation time, contact times up to 60 min had been examined and no further bromination was detected. A contact time of 5 minutes was necessary for the bleaching of the dye colour by the residual bromine and the colour of both dye solutions remain stable for at least two hours after mixing with the reaction mixture.

 

Method validation

The developed methods were validated according to international conference of harmonization guidelines. (51)  The linearity range of absorbance as a function of drug concentration (Table 1) provide an accurate measure of sensitivity of reagents used. Calibration curves have correlation coefficients (r) higher than 0.999 indicating good linearity. The accuracy of the methods were determined by investigating the recovery of drugs at concentration levels covering the specified range (three replicates of each concentration). The results showed excellent recoveries (table 2).Intraday precision was evaluated by calculating standard deviation (SD) of five replicate determinations using the same solution containing pure drug at three different levels. The SD values revealed the high precision of the methods (values vary from 0.89 to 1.12). For inter-day reproducibility on a day-to-day basis, a series was run, in which the standard drug solution at three levels was analyzed each for five days. The day-to-day SD values were in the range of 1.09-1.84. The limit of detection (LD) and limit of quantitation (LQ) were calculated.

 

 


 

Table (1) Analytical parameters for the determination of mentioned drugs  using proposed methods.

Parameters

 

Methyl orange

Methylene blue

Lamotrigine

Minoxidil

Cefixime

Lamotrigine

Minoxidil

Cefixime

Bromate mixture volume, ml

0.5

1.0

1.0

0.5

1.0

1.0

Dye volume, ml

1.0

1.0

0.5

1.0

1.0

0.5

Time before dye addition, min

5

5

15

5

5

15

λmax, nm

508

508

508

667

667

747

Beer's law limits µg/ml

4.0 – 30.0

0.5 – 4.0

0.5 – 5.0

5.0 – 40.0

0.5 – 7.0

2.0 – 5.5

Regression equation*

 

 

 

 

 

 

Intercept

0.0471

-0.1653

-0.043

0.043

0.0614

-0.569

Slope

.035

0.353

0.278

0.0264

0.123

0.334

Correlation Coefficient

0.99978

0.99976

0.99988

0.99986

0.99969

0.99966

*A = a + b C, where C = concentration of drug in μg mL-1, A = absorbance, a = intercept, b = slope.


 

 

According to ICH guidelines, the obtained values indicated high sensitivity of the proposed methods. The robustness of the methods was evaluated by making small changes in the volume of acid [method A (methyl orange 1.0 , 1,5 and 2.0 ml of 5 M HCl and methylene blue 2.0, 2.5 and 3.0 ml 5M HCl] and contact time and the effect of the changes was studied on the percent recovery of the drug. The changes had negligible influence on the results as revealed by small SD values (≤ 1.93)

Application

Some Pharmaceutical formulations containing stated drugs have been successfully analyzed by the proposed methods. Excipients did not show interference. Results obtained were compared to those obtained by applying reference methods and Student’s t-test and F-test were performed for comparison. Results are shown in table 3, 4 and 5.

 


 

Table(2).  Results of the analysis for determination of mentioned drugs using proposed methods.

Parameters

 

Methyl orange

Lamotrigine

Minoxidil

Cefixime

Taken µg/ml

Found µg/ml

Recovery %

Taken µg/ml

Found µg/ml

Recovery %

Taken µg/ml

Found µg/ml

Recovery %

 

4

3.99

99.92

0.5

0.51

102.23

0.5

0.50

100.90

 

5

5.05

101.09

1

1.01

100.73

1

0.98

98.31

 

8

7.94

99.26

1.5

1.49

99.29

1.5

1.50

100.33

 

10

10.11

101.13

2

2.01

100.27

2

1.99

99.54

 

12

12.11

100.95

2.5

2.49

99.61

2.5

2.51

100.21

 

15

14.89

99.24

3

2.97

98.98

3

3.02

100.78

 

20

19.89

99.44

4

4.03

100.68

3.5

3.52

100.47

 

24

23.83

99.30

 

 

 

4

3.99

99.70

 

25

24.92

99.67

 

 

 

4.5

4.47

99.34

 

30

30.26

100.87

 

 

 

5

5.01

100.27

Mean

 

 

100.09

 

 

100.26

 

 

99.98

±S D

 

 

0.82

 

 

1.10

 

 

0.78

±RSD

 

 

0.82

 

 

1.10

 

 

0.78

±SE

 

 

0.37

 

 

0.49

 

 

0.35

Variance

 

 

0.68

 

 

1.21

 

 

0.61

Slope

 

 

0.03

 

 

0.35

 

 

0.28

LD

 

 

0.049

 

 

0.064

 

 

0.053

LQ

 

 

0.164

 

 

0.214

 

 

0.176

S.S.

 

 

0.05

 

 

0.01

 

 

0.005

Molar absorbitivity

L.Mol-1.cm-1

1.0164 X104

4.8556 X104

1.02405X105

 

 

Parameters

 

Methylene blue

Lamotrigine

Minoxidil

Cefixime

Taken µg/ml

Found µg/ml

Recovery %

Taken µg/ml

Found µg/ml

Recovery %

Taken µg/ml

Found µg/ml

Recovery %

 

5

5.08

101.58

0.5

0.51

101.88

2

1.99

99.50

 

10

10.08

100.81

1

0.96

95.67

2.5

2.48

99.32

 

15

15.01

100.05

1.5

1.49

99.56

3

2.99

99.73

 

20

19.86

99.29

2

2.01

100.69

3.5

3.53

100.97

 

25

24.90

99.59

2.5

2.53

101.05

4

4.03

100.78

 

30

29.79

99.29

3

2.97

99.11

4.5

4.47

99.30

 

35

35.24

100.69

5

5.09

101.75

5

4.99

99.85

 

40

40.05

100.14

6

5.98

99.70

5.5

5.50

100.03

 

 

 

 

7

6.96

99.40

 

 

 

Mean

 

 

100.18

 

 

99.87

 

 

99.93

±S D

 

 

0.81

 

 

1.88

 

 

0.64

±RSD

 

 

0.81

 

 

1.88

 

 

0.64

±SE

 

 

0.36

 

 

0.84

 

 

0.28

Variance

 

 

0.66

 

 

3.53

 

 

0.40

Slope

 

 

0.03

 

 

0.12

 

 

0.33

LD

 

 

0.47

 

 

0.133

 

 

0.071

LQ

 

 

1.56

 

 

0.444

 

 

0.236

S.S.

 

 

0.06

 

 

0.01

 

 

0.01

Molar absorbitivity

L.Mol-1.cm-1

7.518 X103

3.3422 X104

6.6928 X104

 


 

 

 

Table (3). Statistical analysis of results obtained by the proposed methods applied on Performa® lotion compared with comparison method

Parameters

Methyl orange

Methylene blue

Comparison method(29)

N

6

8

6

Mean Recovery

99.9

100.1

99.9

Variance

0.79

0.48

1.0

±S.D.

0.89

0.70

1.0

±R.S.D.

0.89

0.70

1.0

±S.E.

0.36

0.25

0.5

Student-t(50)

0.0146 (2.02)

0.435   (1.90)

 

F-test(50)

1.27 (5.05)

2.08 (4.17)

 

              

Table (4). Statistical analysis of results obtained by the proposed methods applied on Lamotrine® tablets compared with reference method

Parameters

Methyl orange

Methylene blue

Comparison method(49)

N

6

6

6

Mean Recovery

99.87

99.99

100.1

Variance

0.789

0.94

2.2

±S.D.

0.89

0.97

1.5

±R.S.D.

0.89

0.97

1.5

±S.E.

0.36

0.40

0.7

Student-t(50)

0.326 (2.02)

0.1534 (2.02)

 

F-test(50)

2.79 (5.05)

2.34 (5.05)

 

 

Table (5). Statistical analysis of results obtained by the proposed methods applied on Ximacef® tablets compared with reference method

Parameters

Methyl orange

Methylene blue

Comparison method(44)

N

7

6

6

Mean Recovery

100.4

99.96

99.93

Variance

1.33

0.51

0.63

±S.D.

1.15

0.71

0.79

±R.S.D.

1.15

0.71

0.79

±S.E.

0.44

0.29

0.35

Student-t(50)

0.865 (1.94)

0.069 (2.02)

 

F-test(50)

2.11 (4.39)

1.235 (5.05)

 

 

 


CONCLUSION:

Two new spectrophotometric methods for determination of lamotrigine, minoxidil and cefixime have been developed based on insitu generation of bromine and using methyl orange or methylene blue as chromogenic agents. They proved to be rapid, accurate, sensitive and reproducible.  

 

REFERENCES:

1.       British Pharmacopoeia, HM Stationery Office, London, UK, PA, 2007,

2.       Martindale: The Complete Drug Reference, Pharmaceutical Press;35 edition (2007)

3.       Bompadre, S. Tagliabracci, A. Battino, M. Giorgetti, R. Determination of lamotrigine in whole blood with on line solid phase extraction.  J Chromatogr B, 2008, 863 (1), 177-180.

4.       Budakova, L. Brozmanove, H. Grundmann, M. Fischer, J. Simultaneous determination of antiepileptic drugs and their two active metabolites by HPLC. J sep sci, 2008, 31 (1), 1-8.

5.       Vermeij, T. A. C. Edelbroek, P. M. Robust isocratic high performance liquid chromatographic method for simultaneous determination of seven antiepileptic drugs including lamotrigine, oxcarbazepine and zonisamide in serum after solid-phase extraction. J Chromatogr B, 2007, 857 (1), 40-46.

6.       Saracino, M. A. Bugamelli, F. Conti, M. Amore, M. Raggi, M. A. Rapid   HPLC analysis of the antiepileptic lamotrigine and its metabolites in human plasma. J Sep Sci, 2007, 30 (14), 2249-2255

7.       Doig, M. V. Clare, R. A. Use of thermospray liquid chromatography - mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, lamotrigine.  J Chromatogr, 1991, 554 (1-2), 181-189

8.       Dasgupta, A. Hart, A. P. Lamotrigine analysis in plasma by gas chromatography-mass spectrometry after conversion to a t-butyldimethylsilyl derivative. J Chromatogr B, 1997, 693 (1), 101-107

9.       Watelle, M. Demedts, P. Franck, F. De Deyn, P. P. Wauters, A. Neels, H. Analysis of the antiepileptic phenyltriazine compound lamotrigine using gas chromatography with nitrogen-phosphorus detection.  Ther Drug Monit, 1997, 19 (4), 460-464

10.    Patil, K. M. Bodhankar, S. L. High-performance thin-layer chromatographic determination of lamotrigine in serum. J Chromatogr B, 2005, 823 (2), 152-157

11.    Theurillat, R. Kuhn, M. Thormann, W. Therapeutic drug monitoring of lamotrigine using capillary electrophoresis. Evaluation of assay performance and quality assurance over a 4-year period in the routine arena.  J Chromatogr, 2002, 979 (1-2), 353-368

12.    Shihabi, Z. K. Oles, K. S. Serum lamotrigine analysis by capillary electrophoresis.  J Chromatogr B, 1996, 683 (1), 119-123

13.    Alizadeh, N. Khakinahad, R.  Jabbari, A.  Spectrophotometric determination of lamotrigine in pharmaceutical preparations and urine by charge-transfer complexation. Pharmazie, 2008, 63(11),  791-795.

14.    Youssef, N.   Taha, E.  Development and validation of spectrophotometric, TLC and HPLC methods for the determination of lamotrigine in presence of its impurity. Chem Pharm Bull (Tokyo). 2007 ;55 (4):541.

15.    RS Talekar, AS Dhake, DB Sonaje, V K. Mourya. Spectrophotometric determination of lamotrigine. Indian J Pharm sci. 2000; 62(1): 51-2

16.    Burgoa Calvo, M. E. Dominguez Renedo, O. Arcos Martinez, M. J. Determination of lamotrigine by adsorptive stripping voltammetry using silver nanoparticle-modified carbon screen-printed electrodes.  Talanta, 2007, 74 (1), 59-64

17.    Gupta, V. K. Singh, A. K. Gupta, B. Development of membrane electrodes for selective determination of some antiepileptic drugs in pharmaceuticals, plasma and urine. Anal Bioanal Chem, 2007, 389 (6), 2019-2028

18.    Sailstad, J. M. Findlay, J. W. A. ,Immunofluorimetric assay for lamotrigine (lamictal) in human plasma.”  Ther Drug Monit, 1991, 13 (5), 433-442

19.    Biddlecombe, R. A. Dean, K. L.Smith, C. D. Jeal, S. C. Validation of a radioimmunoassay for the determination of human plasma concentrations of lamotrigine.  J Pharmaceut Biomed, 1990, 8 (8-12), 691-694

20.    Huang, T. H. Garceau, M. E. Ramstad, T. Stehle, R. G. Rapid determination of trace amounts of minoxidil in hamster skin follicles with various formulations using narrow-bore LC/EC.  J Pharmaceut Biomed, 2005, 38 (3), 532-536

21.    Zarghi, A. Shafaati, A. Foroutan, S. M. Khaddam, A. Rapid determination of minoxidil in human plasma using ion-pair HPLC. J Pharmaceut Biomed, 2004, 36 (2), 377-379

22.    Gagliardi,-L Amato,-A Turchetto,-L. Tonelli,-D. Simultaneous determination of minoxidil and tretinoin in pharmaceutical and cosmetic formulations by reversed-phase HPLC. Anal Lett. 1991 24(10), 1825-1835

23.    Kaniewska,-T. Kublin,-E. Kwiatkowska,-B. Gas-chromatographic determination of minoxidil in serum. Farm. Pol., 1987, 43 (9), 508-511

24.    Fanali, S. Cristalli, M. Catellani, P. Determination of minoxidil in pharmaceutical forms by capillary isotachophoresis.   J Chromatogr, 1987, 405, 385-388

25.    Mahrous,-MS. Abdel-Khalek,-MM. Beltagy,-YA. Simultaneous quantitation of minoxidil and tretinoin [retinoic acid] in magistral and pharmaceutical preparations by first-derivative spectrophotometry. Anal Lett.  1992; 25(9): 1673-1686

26.    Ruiz-Medina, A. Fernandez-de Cordova, M. L. Molina-Diaz, A. Integrated flow injection-solid phase spectrophotometric determination of minoxidil.  Talanta, 1999, 50 (2), 277-282

27.    Sastry,-CSP. Sailaja,-A. Rao,-TT. Krishna,-DM. Extractive spectrophotometric determination of some antihypertensive agents with Supracen violet 3B.  Indian-Drugs.  Aug 1992; 29(11): 473-477

28.    Sastry,-CSP. Sailaja,-A. Rao,-TT. Krishna,-DM. Note on the estimation of minoxidil in pharmaceutical preparations by ion-pair extraction method. Indian-Drugs.  1992; 29(11): 473-477

29.    Arcos, J. Garcia, B.; Munguia, A. Lopez Palacios, J. Kauffmann, J. M. Partiarche, G. J. Spectrophotometric and electro-analytical study of minoxidil.  Anal Lett.  1991, 24 (3), 357-376

30.    Sastry, C. S. P. Sailaja, A. Thirupathi Rao, T. Suryanarayana, M. Simple spectrophotometric method for the determination of minoxidil. Microchem j. 1991, 44 (3), 268-271 

31.    El-Sayed Mahrous, M. Three methods for the quantitative determination of minoxidil. Anal Lett. 1991, 24 (11), 2017-2032

32.    Amankwa, L. Chatten, L. G. Pons, S. Electrochemical studies on minoxidil and its determination in tablets by differential pulse polarography. The Analyst, 1983, 108 (1291), 1221-1226

33.    Shah, P. B.; Pundarikakshudu, K.; Journal of AOAC International, 2006, 89 (4), 987-994

34.    Meng, F.; Chen, X. Y.; Zeng, Y. L.; Zhong, D. F.; J.Chromatography B: Anal. Technol. Biomed. Life Sci., 2005, 819 (2), 277-282

35.    Manna, L.; Valvo, L.; Chromatographia , 2004, 60 (11-12), 645-649

36.    Gonzalez-Hernandez, R.; Nuevas-Paz, L.; Soto-Mulet, L.; Lopez-Lopez, M.; Hoogmartens, J.; Journal of Liquid Chromatography and Related Technologies, 2001, 24 (15), 2315-2324

37.    Nahata, M. C.; Journal of Liquid Chromatography and Related Technologies, 1991, 14 (20), 3755-3759

38.    Eric-Jovanovic, S.; Agbaba, D.; Zivanov-Stakic, D.; Vladimirov, S.; J. Pharm. and Biomed. Anal, 1998, 18 (4-5), 893-898

39.    Solangi, A. R.*; Memon, S. Q.; Khuhawar, M. Y.; Bhanger, M. I.; Acta Chromatographica, 2007 (19), 81-96

40.    Honda, S.; Taga, A.; Kakehi, K.; Koda, S.; Okamoto, Y.; J. Chromatography, 1992, 590 (2), 364-368

41.    Golcu, A.; Dogan, B.; Ozkan, S. A.; Talanta, 2005, 67 (4), 703-712

42.    Reddy, T. M.; Sreedhar, M.; Reddy, S. J.; J. Pharm. and Biomed. Anal, 2003, 31 (4), 811-818

43.    Ganjali, M. R.; Naji, L.; Poursaberi, T.; Shamsipur, M.; Haghgoo, S.; Analytica Chimica Acta, 2003, 475 (1-2), 59-66

44.    Shankar, D. G.; Sushma, K.; Lakshmi, R. V.; Reddy, M. N.; Murthy, T. K.; Rao Srinivasa, Y.; Indian Drugs, 2001, 38 (12), 617-619

45.    Al-Momani, I. F.; J. Pharm. and Biomed. Anal, 2001, 25 (5-6), 751-757

46.    El Walily, A. F. M.; Gazy, A. A. K.; Belal, S. F.; Khamis, E. F.; Spectroscopy Letters, 2000, 33 (6), 931-948

47.    El-Walily, A. F. M.; Gazy, A. A.; Belal, S. F.; Khamis, E. F.; J. Pharm. and Biomed. Anal, 2000, 22 (2), 385-392

48.    Bebawy, L. I.; El Kelani, K.; Abdel Fattah, L.; J. Pharm. and Biomed. Anal, 2003, 32 (6), 1219-1225

49.    personal communication with Delta Pharm.(10th of Ramadan, Egypt)

50.    Modern Analytical Chemistry, David Harvey,  McGraw-Hill Companies, first edition, 2002

51.    Guidance for Industry : Q2B of Analytical  Procedures; Methodololgy: International Conference of  Harmonization (ICH). Nov. 1996 (http:/ www.fda.gov/eder/guidance /1320fnl.pdf)

52.    M. John Plater, ARKIVOC 2003 (i) 37-42

 

 

 

 

 

 

 

Received on 12.02.2012       Accepted on 28.02.2012     

© Asian Pharma Press All Right Reserved

Asian J. Pharm. Ana. 2(1): Jan.-Mar. 2012; Page 22-28